Novartis CEO-Designate Set To Bring More Automation To Drug Discovery
Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.
You may also be interested in...
As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry was preparing for the debate it's eventually getting to have.
Artificial intelligence companies focused on the life science sector have boomed in the past decade. Many of these firms are working with pharma partners and a small number are pursuing their own drug development pipelines.
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.